An Open-Label, Single-Center Phase I Clinical Trial to Estimate Safety of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent Xiamen Innovax Biotech (Primary)
- Indications Cervical cancer; Condylomata acuminata
- Focus Adverse reactions
Most Recent Events
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Jul 2020 Planned End Date changed from 1 Apr 2020 to 1 Jan 2021.
- 20 Dec 2019 Planned End Date changed from 1 Sep 2019 to 1 Apr 2020.